Statement: Zantac (ranitidine) litigation – Kimbrow case
GSK plc (LSE/NYSE: GSK) has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.
Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.